Product Information
CLONAZEPAM 2 MG ODT is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.8792 per EA under NDC 62332036806. Its NADAC has been published 359 times since Nov 20, 2019.
FDA first approved this application on Jun 28, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332036806
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA211033FDA Approved
6/28/2019
TE Code
AB
On Market Since
7/1/2019
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 2 MG ODT has been published 359 times since Nov 20, 2019, and over the history we have for it it has declined 12.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8792 per EA |
|---|---|
| All-time high | $1.3259 (Sep 15, 2021) |
| All-time low | $0.6478 (Jan 17, 2024) |
| 52-week high | $1.0328 |
| 52-week low | $0.8327 |
| Median price | $1.0023 |
| Average price | $1.0065 |
| Largest weekly change | +63.3% (Mar 20, 2024) |
| Weeks tracked | 359 |
| Tracking since | Nov 20, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CLONAZEPAM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CLONAZEPAM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 2 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 2 MG ODT, manufactured by Alembic Pharmaceuticals Inc., is $0.8792 per EA (NDC 62332036806), effective Sep 30, 2026.
How has the price of CLONAZEPAM 2 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 2 MG ODT has declined 12.7%. It has been tracked across 359 weekly CMS publications since Nov 20, 2019.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 2 MG ODT?
Since Nov 20, 2019, the NADAC for CLONAZEPAM 2 MG ODT has ranged from a low of $0.6478 (Jan 17, 2024) to a high of $1.3259 (Sep 15, 2021), with a median of $1.0023 per EA.
Are there cheaper alternatives to CLONAZEPAM 2 MG ODT?
No other NADAC-published product currently shares the active ingredient and strength of CLONAZEPAM 2 MG ODT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLONAZEPAM 2 MG ODT?
CLONAZEPAM 2 MG ODT (NDC 62332036806) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.